DSGN - CIK 0001807120
Design Therapeutics, Inc. trades as DSGN. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$69.79M. This page tracks Design Therapeutics, Inc. through 252 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-04-28 |
| Major company event | 8-K | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Insider trade | 4 | 2026-04-01 |
The largest companies sharing Design Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Design Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025.
In its latest fiscal year Design Therapeutics, Inc. reported a net loss of $69.79M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.